| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 40.6 | 38.4 |
| Gross profit | 13.5 | 15.9 |
| Profit before tax | -37.6 | -37.6 |
| Net income | -37.8 | -38.0 |
| EPS (diluted, $ a share) | $-0.12 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5.5% |
|---|---|
| Gross margin | 33.2% |
| Operating margin | -91.2% |
10-Q filed with the SEC, NASDAQ: PACB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pacific Biosciences of California, Inc.: key numbers
- Share price
- $1.84Close, Nov 16
- Market cap
- $576M
- Shares outstanding
- 312.93MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pacific Biosciences of California, Inc.
All →Pacific Biosciences of California Capital Raise
Pacific Biosciences of California entered into a sales agreement with Allen & Company LLC to establish an at-the-market (ATM) equity offering program. The company may sell up to $100 million of its common stock from time to time at its discretion. Allen & Company will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds.
- Counterparty
- Allen & Company LLC
Pacific Biosciences of California Financial Results
Pacific Biosciences reported Q3 2026 revenue of $40.6 million, driven by demand for its Revio and Vega sequencing systems. Alongside the results, the company announced that CFO Jim Gibson has stepped down and transitioned to an advisory role, with CEO Mark Van Oene serving as interim CFO during a search for a permanent successor.
- Term
- Q3 2026
“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”
Mark Van Oene, President and Chief Executive Officer
Pacific Biosciences of California Insider James R. Gibson II Sells $2.06M of Stock
James R. Gibson II sold 661,815 shares of Pacific Biosciences of California, Inc. at $3.11 a share, worth $2.06M in total on Oct 6, 2026. Shares held after the trade: 1,083,848 (-37.9%).
- Value
- $2.06M
- Shares
- 661,815
- Price
- $3.11
- Holding change
- -37.9%
- Trade date
- Oct 6, 2026